Evome Medical Technologies Inc.
EVMT.V
TSX
| Weiss Ratings | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.12 | |||
| Price History | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -11.11% | |||
| 30-Day Total Return | -20.00% | |||
| 60-Day Total Return | -46.67% | |||
| 90-Day Total Return | -33.33% | |||
| Year to Date Total Return | -44.83% | |||
| 1-Year Total Return | -68.00% | |||
| 2-Year Total Return | -77.14% | |||
| 3-Year Total Return | -87.88% | |||
| 5-Year Total Return | -30.62% | |||
| 52-Week High % Change | -94.92% | |||
| 52-Week Low % Change | 50.00% | |||
| Price | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.30 | |||
| 52-Week Low Price | $0.01 | |||
| 52-Week Low Price (Date) | Mar 31, 2025 | |||
| 52-Week High Price (Date) | Apr 05, 2024 | |||
| Valuation | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 866.83K | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.21 | |||
| Earnings Per Share Growth | 226.32% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.04 | |||
| Price/Book (Q) | -0.49 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.08 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 91.16M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | $0.01 | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | $0.01 | |||
| Company Info | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800 760 6826 | |||
| Address | 49 Natcon Drive Shirley, NY 11967-4704 | |||
| Website | www.evomemedical.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -18.71% | |||
| Profit Margin | -51.90% | |||
| Management Effectiveness | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -- | |||
| Return on Equity | -- | |||
| Income Statement | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | 33.36M | |||
| Revenue Per Share | $0.37 | |||
| Gross Profit (TTM) | -3.38M | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -- | |||
| Net Income (TTM) | -17.31M | |||
| Net Income Avl. to Common (TTM) | -17.31M | |||
| Total Revenue Growth (Q YOY) | -50.78% | |||
| Earnings Growth (Q YOY) | -137.82% | |||
| EPS Diluted (TTM) | -0.21 | |||
| EPS Diluted Growth (Q YOY) | -132.17% | |||
| Balance Sheet | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.05M | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 12.89M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -2.54M | |||
| Current Ratio (Q) | 0.514 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 26.00M | |||
| Total Current Liabilities (Q) | 25.06M | |||
| Total Debt (Q) | 12.93M | |||
| Total Liabilities (Q) | 28.54M | |||
| Total Common Equity (Q) | -2.54M | |||
| Cash Flow | EVMT.V - TSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -26.70K | |||
| Cash from Financing (TTM) | -4.45M | |||
| Net Change in Cash (TTM) | 256.20K | |||
| Levered Free Cash Flow (TTM) | -- | |||
| Cash from Operations (TTM) | 3.95M | |||
